Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director | August 25, 2026 | August 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date August 25, 2026 · Filed August 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,596 |
Ending reported balance
After 2026-08-25 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-08-25 · Exercise / conversion · Acquired 21,132 · Balance 52,728 Row 2 · 2026-08-25 · Exercise / conversion · Acquired 12,429 · Balance 65,157 Row 3 · 2026-08-25 · Sale · Disposed 33,561 · Balance 31,596 F1: This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $194.12 · Expires 2033-05-26 | Direct | 7,044 |
Reported balance
After 2026-08-25 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-25 · Exercise / conversion · Disposed 21,132 · Balance 7,044 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $208.44 · Expires 2034-05-31 | Direct | 12,429 |
Reported balance
After 2026-08-25 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-25 · Exercise / conversion · Disposed 12,429 · Balance 12,429 |
| Common StockSEC Table I · non-derivative | Indirect2024 GRAT | 5,423 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,423 |
| Common StockSEC Table I · non-derivative | Indirect2025 GRAT | 10,780 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 10,780 |
| Common StockSEC Table I · non-derivative | Indirect2026 GRAT | 20,000 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 20,000 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 155,611 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 155,611 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust Held By Spouse | 10,000 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 10,000 |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2022 Filed Feb 17, 2022 21:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 325 | $308.23 | $100,173.91 |
DisclosureSEC source: 0001127602-22-005478 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,077 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $307.75 to $308.46. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 25,108 | $312.24 | $7,839,721.92 |
DisclosureSEC source: 0001127602-22-002789 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,402 F4 · balance_after: On 11/18/2021, the reporting person contributed 8,000 shares of CRL Common Stock to a grantor retained annuity trust for the benefit of himself and his adult children. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 65,011 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-002789 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,510 F3 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on February 22, 2019. F4 · balance_after: On 11/18/2021, the reporting person contributed 8,000 shares of CRL Common Stock to a grantor retained annuity trust for the benefit of himself and his adult children. Read SEC document |
| October 26, 2021 Filed Feb 1, 2022 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 14,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-002789 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · 2019 GRAT Disclosed balance after: 0 F1 · shares: On 10/26/2021: 14,813 shares were gifted from the 2019 GRAT account to Mr. Foster's children. F2 · ownership.nature: On 10/26/2021: 4,200 shares were transferred from the 2019 GRAT account to Direct Holdings. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 15:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $405.00 | $40,500.00 |
DisclosureSEC source: 0001127602-21-023425 · form4.xml · nonDerivative · entry 6 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,299 Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 15:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 808 | $403.92 | $326,364.37 |
DisclosureSEC source: 0001127602-21-023425 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,399 F4 · price: This transaction was executed in multiple trades at prices ranging from $403.385 to $404.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 15:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,552 | $402.71 | $625,007.32 |
DisclosureSEC source: 0001127602-21-023425 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,207 F3 · price: This transaction was executed in multiple trades at prices ranging from $402.33 to $403.18. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 15:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 3,718 | $401.77 | $1,493,798.33 |
DisclosureSEC source: 0001127602-21-023425 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,759 F2 · price: This transaction was executed in multiple trades at prices ranging from $401.31 to $402.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 15:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 3,822 | $400.89 | $1,532,197.38 |
DisclosureSEC source: 0001127602-21-023425 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,477 F1 · price: his transaction was executed in multiple trades at prices ranging from $400.31 to $401.305. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 15:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023425 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,299 Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 16:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 9,577 | $0.00 Strike: $179.66 | $0.00 |
DisclosureSEC source: 0001127602-21-018882 · form4.xml · derivative · entry 19 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,733 Underlying: Common Stock · 9,577 shares Expires 2030-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 16:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 39 | $338.84 | $13,214.62 |
DisclosureSEC source: 0001127602-21-018882 · form4.xml · nonDerivative · entry 12 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,799 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F11 · price: This transaction was executed in multiple trades at prices ranging from $338.53 to $338.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 16:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 316 | $338.27 | $106,893.29 |
DisclosureSEC source: 0001127602-21-018882 · form4.xml · nonDerivative · entry 11 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,838 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F10 · price: This transaction was executed in multiple trades at prices ranging from $338.08 to $338.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 16:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 11 | $337.50 | $3,712.45 |
DisclosureSEC source: 0001127602-21-018882 · form4.xml · nonDerivative · entry 10 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,154 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 16:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 257 | $335.66 | $86,263.36 |
DisclosureSEC source: 0001127602-21-018882 · form4.xml · nonDerivative · entry 9 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,165 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $335.56 to $336.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 16:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 172 | $334.98 | $57,616.44 |
DisclosureSEC source: 0001127602-21-018882 · form4.xml · nonDerivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,422 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $334.77 to $335.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 16:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 503 | $333.97 | $167,985.95 |
DisclosureSEC source: 0001127602-21-018882 · form4.xml · nonDerivative · entry 7 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,594 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $333.66 to $334.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 16:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,638 | $333.02 | $545,487.74 |
DisclosureSEC source: 0001127602-21-018882 · form4.xml · nonDerivative · entry 6 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,097 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $332.63 to $333.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 16:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4,551 | $331.95 | $1,510,698.53 |
DisclosureSEC source: 0001127602-21-018882 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,735 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $331.59 to $332.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 16:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 428 | $331.13 | $141,722.61 |
DisclosureSEC source: 0001127602-21-018882 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,286 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $330.53 to $331.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 16:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,189 | $330.07 | $392,453.11 |
DisclosureSEC source: 0001127602-21-018882 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,714 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $329.76 to $330.445. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 16:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 473 | $329.18 | $155,701.19 |
DisclosureSEC source: 0001127602-21-018882 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,903 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $328.52 to $329.405. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 16:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 9,577 | $179.66 | $1,720,603.82 |
DisclosureSEC source: 0001127602-21-018882 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2021 Filed Jun 2, 2021 14:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 1,273 | $337.99 | $430,261.27 |
DisclosureSEC source: 0001127602-21-018619 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,799 Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 14:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 18,869 | $337.99 Strike: $337.99 | $6,377,533.31 |
DisclosureSEC source: 0001127602-21-018619 · form4.xml · derivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,869 Underlying: Common Stock · 18,869 shares Expires 2031-05-28 F1 · shares: Stock Options vest as follows: 4,717 on May 28, 2022, 4,717 on May 28, 2023, 4,717 on May 28, 2024 and 4,718 on May 28, 2025. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:13 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 606 | $345.85 | $209,582.31 |
DisclosureSEC source: 0001127602-21-016094 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,072 F5 · price: This transaction was executed in multiple trades at prices ranging from $345.36 to $346.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:13 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,300 | $344.60 | $447,975.97 |
DisclosureSEC source: 0001127602-21-016094 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,678 F4 · price: This transaction was executed in multiple trades at prices ranging from $344.34 to $344.82. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:13 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,008 | $343.55 | $689,840.57 |
DisclosureSEC source: 0001127602-21-016094 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,978 F3 · price: This transaction was executed in multiple trades at prices ranging from $343.33 to $344.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:13 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,102 | $342.42 | $377,346.84 |
DisclosureSEC source: 0001127602-21-016094 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,986 F2 · price: This transaction was executed in multiple trades at prices ranging from $342.33 to $342.57. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:13 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,484 | $341.80 | $849,024.74 |
DisclosureSEC source: 0001127602-21-016094 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,088 F1 · price: This transaction was executed in multiple trades at prices ranging from $341.24 to $342.18. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 21:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 24,009 | $0.00 Strike: $88.05 | $0.00 |
DisclosureSEC source: 0001127602-21-007890 · form4.xml · derivative · entry 20 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,009 shares Expires 2022-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 21:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 255 | $289.02 | $73,699.97 |
DisclosureSEC source: 0001127602-21-007890 · form4.xml · nonDerivative · entry 13 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,151 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F12 · price: This transaction was executed in multiple trades at prices ranging from $288.98 to $289.145. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 21:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,466 | $288.33 | $711,029.42 |
DisclosureSEC source: 0001127602-21-007890 · form4.xml · nonDerivative · entry 12 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,406 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F11 · price: This transaction was executed in multiple trades at prices ranging from $287.97 to $288.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 21:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,752 | $287.58 | $791,427.04 |
DisclosureSEC source: 0001127602-21-007890 · form4.xml · nonDerivative · entry 11 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,872 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F10 · price: This transaction was executed in multiple trades at prices ranging from $286.98 to $287.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 21:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4,485 | $286.45 | $1,284,743.95 |
DisclosureSEC source: 0001127602-21-007890 · form4.xml · nonDerivative · entry 10 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,624 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $286.05 to $286.92. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 21:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,993 | $285.48 | $568,955.06 |
DisclosureSEC source: 0001127602-21-007890 · form4.xml · nonDerivative · entry 9 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,109 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $284.98 to $285.885. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 21:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,646 | $284.63 | $753,138.12 |
DisclosureSEC source: 0001127602-21-007890 · form4.xml · nonDerivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,102 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $284.1 to $284.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 21:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,278 | $283.53 | $645,889.77 |
DisclosureSEC source: 0001127602-21-007890 · form4.xml · nonDerivative · entry 7 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,748 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $283.035 to $283.885. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 21:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,656 | $282.49 | $750,280.16 |
DisclosureSEC source: 0001127602-21-007890 · form4.xml · nonDerivative · entry 6 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,026 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $282.035 to $282.8925. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 21:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,191 | $281.65 | $617,095.81 |
DisclosureSEC source: 0001127602-21-007890 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,682 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $280.98 to $281.91. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 21:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,234 | $280.41 | $346,028.16 |
DisclosureSEC source: 0001127602-21-007890 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,873 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $280.03 to $280.905. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 21:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,053 | $279.51 | $294,319.50 |
DisclosureSEC source: 0001127602-21-007890 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,107 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $278.965 to $279.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 21:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 24,009 | $88.05 | $2,113,992.45 |
DisclosureSEC source: 0001127602-21-007890 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 21:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 2,210 | $282.98 | $625,385.80 |
DisclosureSEC source: 0001127602-21-007890 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,151 Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 16:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 20,295 | $0.00 Strike: $109.34 | $0.00 |
DisclosureSEC source: 0001127602-21-007525 · form4.xml · derivative · entry 27 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,296 Underlying: Common Stock · 20,295 shares Expires 2023-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 16:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 984 | $282.78 | $278,255.22 |
DisclosureSEC source: 0001127602-21-007525 · form4.xml · nonDerivative · entry 19 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,361 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F15 · price: This transaction was executed in multiple trades at prices ranging from $282.58 to $282.92 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 16:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,832 | $281.91 | $798,358.08 |
DisclosureSEC source: 0001127602-21-007525 · form4.xml · nonDerivative · entry 18 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,345 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F14 · price: This transaction was executed in multiple trades at prices ranging from $281.59 to $282.42 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 16:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4,259 | $280.96 | $1,196,590.33 |
DisclosureSEC source: 0001127602-21-007525 · form4.xml · nonDerivative · entry 17 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,177 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F13 · price: This transaction was executed in multiple trades at prices ranging from $280.5 to $281.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 16:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 6,474 | $279.97 | $1,812,519.31 |
DisclosureSEC source: 0001127602-21-007525 · form4.xml · nonDerivative · entry 16 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,436 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F12 · price: This transaction was executed in multiple trades at prices ranging from $279.5 to $280.445 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 16:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 925 | $279.31 | $258,365.73 |
DisclosureSEC source: 0001127602-21-007525 · form4.xml · nonDerivative · entry 15 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,910 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F11 · price: This transaction was executed in multiple trades at prices ranging from $278.63 to $279.46. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.